Deadline: 16-Oct-2025
The Conquer Cancer®, the ASCO Foundation, and Pfizer Inc. have launched a collaborative Quality Improvement grant opportunity designed to advance the use of digital technology to improve evidence-based biomarker testing and treatment practices.
This initiative specifically targets colorectal, lung, and prostate cancers, aiming to close gaps in diagnostic testing and ensure timely, data-driven treatment decisions within healthcare systems, hospitals, cancer centers, and other patient care delivery organizations.
The program encourages proposals that begin with assessing current performance gaps in biomarker testing availability and its influence on healthcare professional decision-making. Applicants are expected to involve multidisciplinary teams—including pathology, oncology, and health information specialists—and to collaborate with internal or external technology experts capable of leveraging electronic health records, pathology and laboratory systems, or other patient data sources. Solutions may incorporate advanced technology, process improvements, or artificial intelligence, provided they align with established guidelines for responsible AI use in oncology.
Projects funded under this call are expected to use quality improvement methodologies to introduce sustainable changes that improve timely access to biomarker testing results and adherence to guideline-based treatment plans. Proposals should focus on using data to identify underuse or delays in diagnostic testing, improving test ordering and turnaround times, developing systematic approaches to genetic and biomarker testing, and enhancing adherence to NCCN and ASCO guidelines. The ultimate goal is to improve patient outcomes through better access to diagnostics and targeted therapies, while demonstrating scalable and transferable solutions that can raise the standard of cancer care.
Grants of up to $250,000 are available, supporting projects with a duration of approximately 12 months. Eligible applicants include academic institutions, healthcare systems, hospitals, cancer centers, and other organizations involved in patient care delivery. Applications must be submitted by organizations, not individuals, and collaborations between departments or between institutions are encouraged. Project leads must be employees or contractors of the requesting organization, which must play a central role in implementing the proposed project.
This funding opportunity offers a significant chance for care delivery organizations to drive measurable improvements in cancer care by integrating technology into diagnostic and treatment pathways, ultimately helping patients receive timely, personalized, and effective therapies.
For more information, visit Pfizer.
